

CURRICULUM VITAE

Name: Michael Piers Osborne MD, MS, FRCS, FACS

Address: 428 East 72 Street, Suite 600
New York, NY 10021
Telephone Number: (212) 746-6629
Fax Number: (212) 396-1244
email: osborne@strang.org

Date of Birth: January 6, 1946

Place of Birth: Sutton, Surrey, England

Nationality: United States and United Kingdom

Education: University of London, Charing Cross Hospital
Medical School, 1965-1970

Qualifications:

LRCP	Licentiate, Royal College of Physicians of London	1970
MRCS	Member, Royal College of Surgeons of England	1970
MB	Bachelor of Medicine, University of London	1970
BS	Bachelor of Surgery, University of London	1970
FRCS	Fellow, Royal College of Surgeons of England	1975
MS	Master of Surgery, University of London	1980
MD	University of the State of New York	1981
FACS	Fellow, American College of Surgeons	1984

Postdoctoral Training:

House Physician, West London Hospital (Charing Cross Group of Hospitals)	Internal Medicine July 1, 1970 - December 31, 1970
---	---

House Surgeon to the Professorial Department of Surgery, Fulham Hospital (Charing Cross Group of Hospitals)	General Surgery January 1, 1971 - June 30, 1971
---	--

Institute of Basic Medical Sciences Royal College of Surgeons of England	Surgical Science October 1, 1971 - February 29, 1972
---	---

Senior House Officer, West Middlesex Hospital, Isleworth	Accident and Emergency Surgery March 4, 1972 - September 5, 1972
---	---

Senior House Officer, St. James Hospital, London	General Surgery and Urology October 1, 1972 - March 31, 1973
---	---

Resident Surgical Officer, Brompton Hospital, London	Cardiothoracic Surgery April 1, 1973 - September 30, 1973
---	--

Registrar, West Herts Hospital Hertfordshire	General Surgery, Orthopedics and Traumatology October 1, 1973 - January 11, 1976
Registrar, Charing Cross Hospital, London	General Surgery, Surgical Oncology January 12, 1976 - September 30, 1978
Lecturer in Surgery and Wellcome Trust Fellow Charing Cross Hospital Medical School University of London	Breast Cancer Research January 24, 1977 - January 23, 1978
Honorary Lecturer Senior Registrar in General Surgery, The Royal Marsden Hospital and Institute of Cancer Research, London	Surgical Oncology, Breast Cancer Research November 1, 1978 - June 30, 1980
Fellow in Surgical Oncology, Dept. of Surgery Memorial Sloan-Kettering Cancer Center, NY	Surgical Oncology July 1, 1980-June 30, 1981
<u>Previous Appointments:</u>	
Assistant Professor of Surgery, Cornell University Medical College, NY	July 1, 1981 - June 30, 1984
Assistant Attending Surgeon Memorial Hospital, NY	July 1, 1981 - March 21, 1990
Adjunct Faculty Member, The Rockefeller University, NY	October 1, 1981 - September 30, 1989
Assistant Member, Memorial Sloan-Kettering Cancer Center, NY	July 1, 1984 - March 21, 1990
Associate Professor of Surgery, Cornell University Medical College, NY	July 1, 1984 - November 30, 1991
Head, Breast Cancer Research Laboratory Memorial Sloan-Kettering Cancer Center, NY	July 1, 1986 - August 31, 1991
Associate Member, Memorial Sloan-Kettering Cancer Center, NY	March 22, 1990 - August 31, 1991
Associate Attending Surgeon, Memorial Hospital, NY	March 22, 1990 - August 31, 1991
Director and Chief Executive Officer, Strang Cancer Prevention Center, NY	September 1, 1991 - July 1, 1995

Current Appointments:

Professor of Surgery
Cornell University Medical College, NY

December 1, 1991 - present

President and Chief Executive Officer
Strang Cancer Prevention Center, NY

July 1, 1995 - present

Chief, Breast Service, Department of Surgery
The New York Presbyterian Hospital-Cornell Medical Center, NY

September 1, 1991 - present

Attending Surgeon
The New York Presbyterian Hospital-Cornell Medical Center, NY

September 1, 1991 - present

Director
Strang-Cornell Breast Center, NY

September 1991 – September 30, 2000

Visiting Associate Physician,
The Rockefeller University Hospital, NY

August 1, 1983 – present

Adjunct Professor
The Rockefeller University, NY

July 1, 2003 - present

Licensed Physician#: 145757

1981- New York

Board Certification (equivalent):

1982 Certification of Higher Surgical
Training in General Surgery,
Royal College of Surgeons of England

Scientific and Medical Societies:

American Association for Cancer Research
American Association for the Advancement
of Science
American Medical Association
American Society of Breast Diseases
American Society of Breast Surgeons
American Society of Clinical Oncology
American Surgical Association
Association of Breast Surgery at BASO
British Association for Cancer Research
British Association of Surgical Oncology
Fellow, Royal Society of Medicine
International Society of Surgery
Memorial Hospital Alumni Society
New York Academy of Sciences
New York Cancer Society
New York Clinical Society
New York County Medical Society
New York Metropolitan Breast Cancer Group
New York State Medical Society
New York Surgical Society
Physician's Scientific Society
Society of Surgical Oncology

Honors and Awards:

Undergraduate: The Golding Medal (The Governor's Clinical Gold Medal)
Llewelyn Scholarship
Norman C. Lake Prize in Surgery
William Travers Prize in Obstetrics and Gynecology
Thomas Henry Green Prize in Clinical Medicine
Prize in Orthopedics
Prize in Gynecology
Prize in Radiology
David Winser Essay Prize
Prize in Second Clinical Year Surgery
Certificate of Merit in Psychiatry
Certificate of Merit in Third Clinical Year Medicine
Certificate of Merit in Second Clinical Year Medicine
Certificate of Merit in First Clinical Year Surgery
Certificate of Merit in Anatomy Dissection

Postgraduate: Wellcome Trust Surgical Fellowship (1977 - 1978)
Simpson-Smith Surgical Travel Scholarship (1977)
Raven Prize, British Association of Surgical Oncologists (1978)
Gosse Scholarship, Charing Cross Hospital Medical School (1980)
Albert Segaloff Memorial Lecturer, Atlon Ochsner Medical Foundation (1991)
Cyril S. Avranitis Lecturer, Monmouth Medical Center (1994)
Ellen Dryer Memorial Lecture, Sass Foundation New York (2001)

Other Activities: American Cancer Society Institutional Grants Review Committee,
Memorial Sloan-Kettering Cancer Center 1986-1989
Education Committee, Society of Surgical Oncology 1988-1990
Vice-President, New York Metropolitan Breast Cancer Group 1989-1991
Chairman, Research Committee, New York Metropolitan Breast Cancer Group 1991-1995
Breast Tumor Board, New York Hospital-Cornell Medical Center 1991-present
Cancer Care Committee, New York Hospital-Cornell Medical Center 1991-present
Member, Board of Trustees, Strang Cancer Prevention Center 1991-present
Member, Executive Committee, Strang Cancer Prevention Center 1991-present
Scientific Advisory Board, American-Italian Foundation 1991-present
National Institutes of Health, National Cancer Institute, Workshop on Bone Marrow
Micrometastases 1992
Board of Trustees, National Consortium of Breast Centers 1992-1995
Executive Board, Society for the Study of Breast Disease 1992-1995
Medical Advisory Board, National Alliance of Breast Cancer Organizations 1992-present
Chairman, Program Committee, 20th Annual Symposium of the New York Metropolitan
Breast Cancer Group 1993
Vice-President, New York Metropolitan Breast Cancer Group 1993-1995
Cornell University Medical College Faculty Practice Plan/Clinical Affairs Task Force
on Highly Specialized Services 1995
President, New York Metropolitan Breast Cancer Group 1995-1997
Board of Advisors, New York Menopause Center 1995-present
Secretary General, International Society of Cancer Chemoprevention 1996-2002
Breast Cancer Advisory Board, Schering-Plough, 1996
The New York Hospital-Presbyterian Network, CEO Committee 1997-2000
Editorial Board, Breast Cancer Online 1998-present
Editorial Board, Seminars in Breast Disease 1998-present

Member of the Board, The New York and Presbyterian Healthcare Network 1998-2000
 Breast Cancer Advisory Board, AstraZeneca, 1999
 Treasurer, International Society of Cancer Chemoprevention 2002-present
 Scientific Advisory Board, Sass Foundation
 Committee Member, American Association for Cancer Research – Career Development Award 2002.
 Local Arrangements Committee. Society of Surgical Oncology 57th Annual Cancer Symposium, New York City 2004.

Editorial Boards/Reviewer:

Editorial Board, Breast Cancer On Line
 Reviewer, Annals of Surgical Oncology
 Reviewer, Nature Reviews Drug Discovery
 Reviewer, New England Journal of Medicine
 Reviewer, Lancet
 Reviewer, Cancer Research

Public Recognition:

1989	Good Housekeeping	The 184 Best Breast Cancer Doctors in America
1991	New York Magazine	The Best Doctors in New York
1992	Good Housekeeping	The Best Cancer Specialists in the US
1992-1993	Woodward/White	The Best Doctors in America
1993-present	Marquis	Who's Who in Science & Engineering
1994-present	Marquis	Who's Who in the World
1995	Town & Country	The Best Medical Specialists in North America
1996-present	Marquis	Who's Who Worldwide
1996	American Health	The Best Doctors in America
1996	New York Magazine	The Best Doctors in New York
1997	Castle Connolly	How to Find the Best Doctors in the New York Metro Area
1998	Castle Connolly	How to Find the Best Doctors in the New York Metro Area
1998	New York Magazine	The Best Doctors in New York
1999	Castle Connolly	How to Find the Best Doctors in the New York Metro Area
1999	Good Housekeeping	318 Top Cancer Doctors for Women
2000	Castle Connolly	How to Find the Best Doctors in the New York Metro Area
2000	Manhattan Magazine	5 th Annual Breast Cancer Awareness Award
2000	New York Magazine	The Best Doctors in New York
2001	New York Magazine	The Best Doctors in New York
2001	Castle Connolly	Top Doctors in the New York Metro Area
2001-2002	Best Doctors	Best Doctors in America
2002	New York Magazine	The Best Doctors in New York
2002	Castle Connolly	America's Top Doctors
2003	New York Magazine	The Best Doctors in New York
2003	Castle Connolly	Top Doctors in America
2003-2004	Best Doctors	Best Doctors in America
2004	New York Magazine	The Best Doctors in New York
2004	Smith Barney Citigroup	Extraordinary Achievement Award "Women's Health Issues" in conjunction with the Susan G. Komen Foundation Race for the cure.

Bibliography

1. **Osborne MP**, Paneth M, Hinson KFW.
Starch granules in the pericardium as a cause of post-cardiotomy syndrome.
Thorax 1974;29:199-203
2. **Osborne MP**.
Penile Parkinsonism.
Postgraduate Medical Journal 1974;50:523-524
3. Honey M, Lincoln JCR, **Osborne MP**, DeBono D.
Coarctation of the aorta with right aortic arch.
British Heart Journal 1975;37:937-945
4. **Osborne MP**, Hamilton G, Shalley M.
Axial volvulus of Meckel's diverticulum.
Postgraduate Medical Journal 1978;54:692-693
5. Bion J, Coleman JC, **Osborne MP**.
An unusual postoperative pneumonia.
Journal of the Royal Society of Medicine 1978;71:523-526
6. Ryman BE, Jewkes RF, Jeyasingh K, **Osborne MP**, Patel HM, Richardson VJ, Tyrell DA.
Potential applications of liposomes to therapy.
Annals of the New York Academy of Sciences 1978;308:281-307
7. **Osborne MP**, Murray-Lyon IM, Reynolds K.
Dacron bypass grafting in the relief of obstructive jaundice.
Lancet 1979;1:1323-1325
8. **Osborne MP**, Richardson VJ, Jeyasingh K, Ryman BE.
Radionuclide labeled liposomes - a new lymph node imaging agent.
International Journal of Nuclear Medicine and Biology 1979;6:75-83
9. **Osborne MP**, Jeyasingh K, Jewkes RF, Burns JJ.
The preoperative detection of internal mammary lymph node metastases in breast cancer.
British Journal of Surgery 1979;66:813-818
10. **Osborne MP**.
Lymph node scanning for breast cancer.
Transactions of the Medical Society of London 1979;95:43-45
11. Greening WP, Sarker SK, **Osborne MP**.
Hemiagenesis of the thyroid gland.
British Journal of Surgery 1980;67:446-448
12. Sarker SK, **Osborne MP**, Harmer CL, Greening WP.
Thyroid cancer - a study of 220 cases.
Indian Journal of Cancer 1980;17:11-18

13. **Osborne MP.**
The detection of lymphatic metastases in breast cancer.
Master of Surgery Thesis, University of London, 1980
14. **Osborne MP, Richardson VJ, Jeyasingh K, Ryman BE.**
Potential applications of radionuclide-labeled liposomes in the detection of the lymphatic spread of cancer.
International Journal of Nuclear Medicine, Biology and Physics 1982;9:47-51
15. **Osborne MP, Griffiths JD, Shaw HJ.**
Colon-transposition in the management of upper gastrointestinal cancer.
Cancer 1982;50:257-264
16. Freeman JL, Brondbo K, **Osborne MP**, Novek AM, Shaw HJ, Rubin A, Chapnick JS.
Greater momentum used for carotid cover after pharyngolaryngoesophagectomy and gastric "pull-up" or colonic "swing".
Archives of Otolaryngology 1982;108:685-687
17. **Osborne MP, Payne JH, Richardson VJ, McCready VR, Ryman BE.**
The preoperative detection of axillary lymph node metastases in breast cancer by isotope imaging.
British Journal of Surgery 1983;70:141-144
18. **Osborne MP.**
Pedal microlymphangiography in the experimental animal.
Lymphology 1983;16:31-34
19. **Osborne MP, Rosen PP, Lesser ML, Schwartz MK, Menendez-Botet CJ, Fishman J, Kinne DW, Beattie EJ Jr.**
The relationship between family history, exposure to exogenous hormones and estrogen receptor protein in breast cancer.
Cancer 1983;51:2134-2138
20. Fracchia AA, Cody HS, Eisenberg BL, **Osborne MP**, Owens JC, Weingrad DN, Caron AS, Urmacher C, Bretsky S.
Stage II carcinoma of the breast: The importance of adequate local therapy.
Breast 1983;9:23-29
21. **Osborne MP, Ormiston N, Harmer CL, McKinna JA, Baker J, Greening WP.**
Breast conservation in the treatment of early breast cancer: A 20-year follow-up.
Cancer 1984;53:349-355
22. Petrek JA, Dukoff R, Crowe J, **Osborne MP**, Kinne DW.
Pregnancy-associated breast cancer.
Surgical Forum 1986;38:478-480
23. Axelrod DM, Bockman RS, Wong GY, **Osborne MP**, Kinne DW, Brennan MF.
Distinguishing features of primary hyperparathyroidism in patients with breast cancer.
Cancer 1987;60:160-1624

24. McCormick B, Kinne D, Petrek J, **Osborne MP**, Cox L, Shank B, Hellman S, Yahalom J, Rosen PP. Limited resection for breast cancer: A study of inked specimen margins before radiotherapy. *International Journal of Radiation Oncology, Biology, Physics* 1987;13:1667-1671
25. Cote RJ, Rosen PP, Hakes TB, Sedira M, Bazinet M, Kinne DW, Old LJ, **Osborne MP**. Monoclonal antibodies detect occult breast carcinoma metastases in the bone marrow of patients with early stage disease. *American Journal of Surgical Pathology* 1988;12:333-340
26. Axelrod DM, Menendez-Botet CJ, Kinne DW, **Osborne MP**. Levels of estrogen and progesterone receptor proteins in patients with breast cancer during various phases of the menstrual cycle. *Cancer Investigation* 1988;6:7-14
27. Wesson MF, **Osborne MP**, Petrek J, Kinne D, McCormick B. Iridium-192 implants for primary breast cancer: Experience with concomitant limited resection or re-excision. *Endocurietherapy/Hyperthermia Oncology* 1988;4:149-153
28. McCormick B, Wesson MF, Cox L, **Osborne MP**, Petrek JA, Kinne DW. Iridium-192 implants for primary breast cancer: Experience with placement at the time of wide local excision. *International Journal of Radiation Oncology, Biology and Physics* 1988;15:745-748
29. Telang NT, Basu A, Kurihara H, **Osborne MP**, Modak MJ. Modulation in the expression of murine mammary tumor virus, ras proto-oncogene and of alveolar hyperplasia by fatty acids in mouse mammary explant cultures. *Anticancer Research* 1988;8:971-976
30. **Osborne MP**, Karmali RA, Hershcopf RJ, Bradlow HL, Kourides IA, Williams WR, Rosen PP, Fishman J. Omega-3 fatty acids: modulation of estrogen metabolism and potential for breast cancer prevention. *Cancer Investigation* 1988;6:629-631
31. Dermatis H, Rowland J, Miransky J, Kerner J, **Osborne MP**, Holland J. Consent and compliance in chemoprevention trials. *Cancer Investigation* 1988;6:633-635
32. Kinne DW, Petrek JA, **Osborne MP**, Fracchia AA, DePalo AA, Rosen PP. Breast carcinoma in-situ. *Archives of Surgery* 1989;124:33-36
33. **Osborne MP**, Asina S, Wong GY, Old LJ, Cote RJ. Immunofluorescent monoclonal antibody detection of breast cancer in bone marrow: a study of sensitivity in a model system. *Cancer Research* 1989;49:2510-2513
34. Telang NT, Bradlow HL, Kurihara H, **Osborne MP**. In vitro biotransformation of estradiol by explant cultures of murine mammary tissues. *Breast Cancer Research and Treatment* 1989;13:173-181

35. Baron PL, Moore MP, Kinne DW, Candela FC, **Osborne MP**, Petrek JA.
Occult breast cancer presenting with axillary metastases: updated management.
Archives of Surgery 1990;125:210-215
36. **Osborne MP**, Telang NT, Kaur S, Bradlow HL.
Influence of chemo-preventive agents, tamoxifen and hydroxyphenylretinamide (HPR) on estradiol metabolism and mammary preneoplasia in C3H mice.
Steroids 1990;55:114-119
37. Telang NT, Axelrod DM, Bradlow HL, **Osborne MP**.
Metabolic biotransformation of estradiol in human mammary explant cultures.
Annals of the New York Academy of Sciences 1990;586:70-78
38. Telang NT, Basu A, Modak MJ, **Osborne MP**.
Cellular ras proto-oncogene expression in human mammary explant cultures: A potential marker for chemical carcinogenesis.
Annals of the New York Academy of Sciences 1990;586:230-237
39. Telang NT, **Osborne MP**, Sweterlitsch LA, Narayanan R.
Neoplastic transformation of mouse mammary epithelial cells by deregulated myc expression.
Cell Regulation 1990;1:863-872
40. Dershaw DD, McCormick B, Cox L, **Osborne MP**.
Differentiation of benign and malignant local tumor recurrence after lumpectomy.
American Journal of Roentgenology 1990;155:35-38
41. Seres DS, Bunk MJ, **Osborne MP**, Rivlin RS, Tiwari RK.
Effects of marginal dietary zinc deficiency and vitamin E supplementation on hepatic adenine dinucleotide phosphoribosyl transferase activity in female Sprague-Dawley rats.
Nutrition Research 1991;11:337-345
42. Telang NT, Axelrod DM, Wong GY, Bradlow HL, **Osborne MP**.
Biotransformation of estradiol by explant cultures of human breast tissue.
Steroids 1991;56:37-43
43. Dershaw DD, Panicek DM, **Osborne MP**.
Significance of lymph nodes visualized by the mammographic axillary view.
Breast Diseases 1991;4:271-280
44. Tiwari RK, Wong GY, Mukhopadhyay B, Telang NT, Liu J, Hakes TB, **Osborne MP**.
Interferon-alpha and gamma mediated gene responses in a human breast carcinoma cell line.
Breast Cancer Research and Treatment 1991;18:33-41
45. **Osborne MP**, Asina S, Wong GY, Old LJ, Cote RJ, Rosen PP.
Sensitivity of immunocytochemical detection of breast cancer cells in human bone marrow.
Cancer Research 1991;51:2706-2709
46. Telang NT, Narayanan R, Bradlow HL, **Osborne MP**.
Coordinated expression of intermediate biomarkers for tumorigenic transformation in ras-transfected mouse mammary epithelial cells.
Breast Cancer Research and Treatment 1991;18:155-163

47. Cote RJ, Rosen PP, Lesser ML, Old LJ, **Osborne MP**.
Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases.
Journal of Clinical Oncology 1991;9:1749-1756
48. Telang NT, Kurihara H, Wong GY, Bradlow HL, **Osborne MP**.
Preneoplastic transformation in mouse mammary tissue: identification and validation of intermediate biomarkers for chemoprevention.
Anticancer Research 1991;11:1021-1028
49. Michnovicz JJ, Telang NT, **Osborne MP**, Bradlow HL.
Effects of dietary indole-3-carbinol on estradiol metabolism and spontaneous mammary tumors in mice.
Carcinogenesis 1991;12:1571-1574
50. Tiwari RK, Mukopadhyay B, Telang NT, **Osborne MP**.
Modulation of gene expression by selected fatty acids in human breast cancer cells.
Anticancer Research 1991;11:1383-1388
51. Tiwari RK, Wong GY, Liu I, Miller D, **Osborne MP**.
Augmentation of cytotoxicity using combinations of interferon (types I and II), tumor necrosis factor and tamoxifen in MCF-7 cells.
Cancer Letters 1991;61:45-52
52. **Osborne MP**, Borgen PI, Wong GY, Rosen PP, McCormick B.
Salvage mastectomy for local-regional relapse after breast conserving surgery and radiation therapy.
Surgery, Gynecology and Obstetrics 1992;174:189-194
53. **Osborne MP**, Ruperto JF, Crowe JP, Rosen PP, Telang NT.
The effect of tamoxifen on preneoplastic cell proliferation in N-nitroso-N-methylurea-induced mammary carcinogenesis.
Cancer Research 1992;52:1477-1480
54. Narayanan R, Lawlor KG, Schaapveld RQJ, Cho KR, Vogelstein B, Tran PB-V, **Osborne MP**, Telang NT.
Antisense RNA to the putative tumor-suppressor gene DCC transforms Rat-1 fibroblasts.
Oncogene 1992;7:553-561
55. Telang NT, Suto A, Wong GY, **Osborne MP**, Bradlow HL.
Induction by estrogen metabolite 16 α -hydroxestrone of genotoxic damage and aberrant proliferation in mouse mammary epithelial cells.
Journal of the National Cancer Institute 1992;84:634-636
56. Tiwari RK, Borgen PI, Cordon-Cardo C, **Osborne MP**.
HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis.
Anticancer Research 1992;12:419-426
57. Willard W, Borgen P, Bol R, Tiwari R, **Osborne MP**.
Cowden's Disease: A case report with analyses at the molecular level.
Cancer 1992;69:2969-2974

58. Suto A, Bradlow HL, Wong GY, **Osborne MP**, Telang NT.
Persistent endocrine responsiveness of ras oncogene-transformed mouse mammary epithelial cells.
Steroids 1992;57:262-268
59. Telang NT, Bradlow HL, **Osborne MP**.
Molecular and endocrine biomarkers in non-involved breast: relevance to cancer chemoprevention.
Journal of Cellular Biochemistry 1992;16:161-169
60. Borgen PI, Vlamis V, Potter C, Hoffman B, Wong GY, Kinne DW, **Osborne MP**, McKinnon WMP.
Current management of male breast cancer: A review of 104 cases.
Annals of Surgery 1992;215:451-459
61. Lawler KG, Telang NT, **Osborne MP**, Schaapveld RQ, Cho KR, Vogelstein B, Narayanan R.
Antisense RNA to the putative tumor suppressor gene "Deleted in Colorectal Cancer" transforms fibroblasts.
Annals of the New York Academy of Sciences 1992;660:283-285
62. Yahalom J, Petrek JA, Biddinger PW, Kessler S, Dershaw DD, McCormick B, **Osborne MP**, Rosen PP.
Breast cancer in patients irradiated for Hodgkin's disease: A clinical and pathological analysis of 45 events in 37 patients.
Journal of Clinical Oncology 1992;10:1674-1681
63. Tiwari RK, Mukhopadhyay B, **Osborne MP**.
Desensitization of human breast cancer cells by interferon.
International Journal of Oncology 1992;1:601-605
64. Dershaw DD, McCormick B, **Osborne MP**.
Detection of local recurrence after conservation therapy for breast carcinoma.
Cancer 1992;70:493-496
65. Bradlow HL, Michnovicz JJ, Telang NT, **Osborne MP**, Goldin BR.
Diet, oncogenes and tumor viruses as modulators of estrogen metabolism in vivo and in vitro.
Cancer Prevention and Detection 1992;16:1 S38-S42
66. Suto A, Bradlow HL, Kubota T, Kilajma M, Wong GY, **Osborne MP**, Telang NT.
Alterations in proliferative and endocrine responsiveness of human mammary carcinoma cells by prototypic tumor suppressing agents.
Steroids 1993;58:215-219
67. Breuer B, Kash K, Rosenthal G, Diemer K, **Osborne MP**, Miller DG.
Reporting bilaterality status in first-degree relatives with breast cancer: A validity study.
Genetic Epidemiology 1993;10:245-256
68. Tiwari RK, Guo L, Mukhopadhyay B, Wong GY, **Osborne MP**.
Gene induction by interferons in BT-20 cells.
International Journal of Oncology 1993;481-487
69. Garg A, Suto A, **Osborne MP**, Gupta RC, Telang NT.
Expression of biomarkers for transformation in 7,12-dimethylbenz[a]anthracene-treated mammary epithelial cells.
International Journal of Oncology 1993;3:185-189

70. Breuer B, Luo J, DeVivo I, Pincus M, Tatum AH, Daucher J, Minick R, **Osborne MP**, Miller DG, Nowak E, Cody H, Carney WP, Brandt-Rauf PW.
Detection of elevated c-erbB-2 oncoprotein in the serum and tissue in breast cancer.
Medical Science Research 1993;21:383-384
71. DeVivo I, Breuer B, Smith S, Milling C, Pincus M, Tatum AH, Daucher J, Niman H, Minick R, **Osborne MP**, Miller DG, Nowak E, Cody H, Brandt-Rauf PW.
Detection of serum c-myc oncoprotein in cancer patients by immunoblot.
Medical Science Research 1993;21:345-347
72. **Osborne MP**, Bradlow HL, Wong GYC, Telang NT.
Upregulation of estradiol C16 α -hydroxylation in human breast tissue: A potential biomarker of breast cancer risk.
Journal of the National Cancer Institute 1993;85:1917-1920
73. Suto A, Bradlow HL, Wong GYC, **Osborne MP**, Telang NT.
Experimental down-regulation of intermediate biomarkers of carcinogenesis in mouse mammary epithelial cells.
Breast Cancer Research and Treatment 1993;27:193-202
74. Tiwari RK, Guo L, Bradlow HL, Telang NT, **Osborne MP**.
Selective responsiveness of human breast cancer cells to indole-3-carbinol, a chemopreventive agent.
Journal of the National Cancer Institute 1994;86:126-131
75. Sepkovic DW, Bradlow HL, Michnovicz J, Murtezani S, Levy I, **Osborne MP**.
Catechol estrogen production in rat microsomes after treatment with indole-3-carbinol, ascorbigen, or B-naphthaflavone: A comparison of stable isotope dilution gas chromatography-mass spectrometry and radiometric methods.
Steroids 1994;59:318-322
76. Telang NT, Bradlow HL, **Osborne MP**.
Effect of tamoxifen on mammary preneoplasia: Relevance to chemopreventive intervention
Cancer Detection and Prevention 1994;18:313-321
77. **Osborne MP**, Rosen PP.
Detection and management of bone marrow micrometastases in breast cancer.
Oncology 1994;8:25-31
78. Kash KM, Holland JC, Miller DG, **Osborne MP**.
Psychological distress and adherence to screening behaviors in women at genetic risk for breast cancer.
Psychosomatic Medicine 1994;56:148-149
79. Bradlow HL, Michnovicz JJ, Halper M, Miller DG, Wong GY, **Osborne MP**.
Long-term responses of women to indole-3-carbinol or a high fiber diet.
Cancer Epidemiology Biomarkers and Prevention 1994;3:591-595
80. **Osborne MP**, Simmons RM.
Salvage surgery for recurrence after breast conservation.
World Journal of Surgery 1994;18:93-97

81. Shattuck-Eidens D, McClure M, Simard J, Labrie F, Narod S, Couch F, Hoskins K, Weber B, Castilla L, Erdos M, Brody L, Friedman L, Ostermeyer E, Szabo C, King MC, Jharwar S, Offit K, Norton L, Gilewski T, Lubin M, **Osborne MP**, Black D, Boyd M, Steel M, Ingles S, Haile R, Lindblom A, Olsson H, Borg A, Bishop DT, Solomon E, Radice P, Spatti G, Gayther S, Ponder B, Warren W, Stratton M, Liu Q, Fujimura F, Lewis C, Skolnick M, Goldgar E.
A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene.
Journal of the American Medical Association 1995;273:535-541
82. Valdimarsdottir HB, Bovbjerg DH, Kash KM, Holland JC, **Osborne MP**, Miller DG.
Psychological distress in women with a familial risk of breast cancer.
Psycho-Oncology 1995;4:133-141
83. Li G, **Osborne MP**, Tiwari RK.
Anti-proliferative effects of garlic constituents in cultured human breast cancer cells.
Oncology 1995;2:787-791
84. Fishman J, **Osborne MP**, Telang NT.
The role of estrogen in mammary carcinogenesis.
Annals of the New York Academy of Sciences 1995;768:91-100
85. Araki R, Inoue S, **Osborne MP**, Telang NT.
Chemoprevention of mammary preneoplasia. In-vitro effects of a green tea polyphenol.
Annals of the New York Academy of Sciences 1995;768:215-222
86. Kash KM, Holland JC, **Osborne MP**, Miller DG.
Psychological counseling strategies for women at risk of breast cancer.
Journal of the National Cancer Institute, Monogr. 1995;17:73-79
87. Sepkovic DW, Bradlow HL, Ho G, Hankinson SE, Gong L, **Osborne MP**, Fishman J.
Estrogen metabolite ratios and risk assessment of hormone-related cancers. Assay validation and prediction of cervical cancer risk.
Annals of the New York Academy of Sciences 1995;768:312-316
88. Bradlow HL, Sepkovic DW, Telang NT, **Osborne MP**.
Indole-3-carbinol. A novel approach to breast cancer prevention.
Annals of the New York Academy of Sciences 1996;768:180-200
89. **Osborne MP**.
Hormonal intervention in breast cancer: Past, present and future.
Annals of the New York Academy of Sciences 1996;784:427-432
90. Arzimanoglou II, Lallas T, **Osborne MP**, Barber H, Gilbert F.
Microsatellite instability differences between familial and sporadic ovarian cancers.
Carcinogenesis 1996;9:1799-1804
91. Bradlow HL, Telang NT, Sepkovic DW, **Osborne MP**.
2-Hydroxyestrone: the 'good' estrogen.
Journal of Endocrinology 1996;150:S259-S265

92. Fishman JH, Gonzalez A, **Osborne MP**.
Breast cancer cells cultured in a system of new design presecrete an extracellular matrix and proliferate within it without cell-cell adhesion.
Biochemical and Biophysical Research Communication 1996;220:467-471
93. Bradlow L, Telang NT, **Osborne MP**.
Estrogen metabolites as bioreactive modulators of tumor initiators and promoters.
Advances in Experimental Medical Biology 1996;387:285-296
94. Katdare M, Singhal H, Newmark H, **Osborne MP**, Telang NT.
Prevention of mammary preneoplastic transformation by naturally-occurring tumor inhibitors.
Cancer Letters 1997;111:141-147
95. Telang NT, Katdare M, Bradlow HL, **Osborne MP**.
Estradiol metabolism: An endocrine biomarker for modulation of human mammary carcinogenesis.
Environmental Health Perspectives 1997;105 Suppl:559-564
96. Singhal H, Potter C, **Osborne MP**.
No effect of timing of biopsy in the menstrual cycle on incidence of bone marrow micrometastasis in patients with breast cancer.
Annals of Surgical Oncology 1997; 4:503-505
97. Telang NT, Katdare M, Bradlow HL, **Osborne MP**, Fishman J.
Inhibition of proliferation and modulation of estradiol metabolism: Novel mechanisms for breast cancer prevention by the phytochemical indole-3-carbinol.
Proceedings of the Society for Experimental Biology and Medicine 1997; 216:246-252
98. Simmons RM, **Osborne MP**.
Dilemmas in breast disease: Prophylactic mastectomy.
Breast Journal 1997;3:372-379
99. Zakowski SG, Valdimardottir HB, Bovbjerg DH, Borgen P, Holland J, Kash K, Miller DG, Mitnick J, **Osborne MP**, Van Zee K.
Predictors of intrusive thoughts and avoidance in women with family histories of breast cancer.
Annals of Behavioral Medicine 1997;19:362-369
100. Bergstein I, Eisenberg LM, Bhalerao J, Jenkins NA, Copeland NG, **Osborne MP**, Bowcock AM, Brown AMC.
Isolation of two novel WNT genes, WNT 14 and WNT 15, one of which (WNT15) is closely linked to WNT3 on human chromosome 17q21.
Genomics 1997;46:450-458.
101. Robson M, Dabney MK, Rosenthal G, Ludwig S, Seltzer MH, Gilewski T, Haas B, **Osborne MP**, Norton L, Gilbert F, Offit K.
Prevalence of recurring BRCA mutations among Ashkenazi Jewish women with breast cancer.
Genetic Testing 1997;1:47-51
102. Wong GYC, Bradlow L, Sepkovic D, Mehl S, Mailman J, **Osborne MP**.
Dose-ranging study of indole-3-carbinol for breast cancer prevention.
Journal of Cellular Biochemistry 1997;Supplements 28/29:111-116

103. Telang NT, Inoue S, Bradlow HL, **Osborne MP**.
Negative growth regulation of oncogene-transformed mammary epithelial cells by tumor inhibitors.
Advances in Experimental Medicine and Biology 1997;400A:409-418
104. Gilbert F, Dabney MK, Diemer K, Ludwig S, Rosenthal G, **Osborne MP**.
BRCA1/BRCA2 mutations and breast cancer in Ashkenazi Jewish women.
Annals of the New York Academy of Sciences 1997;833:198-203.
105. Davis DL, Telang NT, **Osborne MP**, Bradlow HL.
Medical hypothesis: bifunctional genetic-hormonal pathways to breast cancer.
Environmental Health Perspectives 1997;105, Suppl3:571-576.
106. Telang NT, Arcuri F, Granata OM, Bradlow HL, **Osborne MP**, Castagnetta L.
Alteration of oestradiol metabolism in myc oncogene-transfected mouse mammary epithelial cells.
British Journal of Cancer 1998; 77:1549-1554
107. Bradlow HL, Sepkovic DW, Klug T, **Osborne MP**.
Application of an improved ELISA assay to the analysis of urinary estrogen metabolites.
Steroids 1998; 63:406-413
108. Giess CS, Keating DM, **Osborne MP**, Ng YY, Rosenblatt R.
Retroareolar breast carcinoma: clinical, imaging, and histopathologic features.
Radiology 1998; 207: 669-673
109. Breuer B, Smith S, Thor A, Edgerton S, **Osborne MP**, Minick R, Cody HS 3rd, Nowak E, Cortese A, Simmons RM, Carney WP, Brandt-Rauf PW.
ErbB-2 protein in sera and tumors of breast cancer patients.
Breast Cancer Research Treatment 1998;49:261-70
110. Oliveria S, Christos PJ, Visintainer PF, McDougall CJ, **Osborne MP**.
Patterns of colon cancer screening among companies in the U.S.: A descriptive survey.
American Journal of Health Promotion 1999;13:146-148.
111. Jinno H, Steiner MG, Mehta RG, **Osborne MP**, Telang NT.
Inhibition of aberrant proliferation and induction of apoptosis in HER-2/*neu* oncogene transformed human mammary epithelial cells by *N*-(4-hydroxyphenyl) retinamide.
Carcinogenesis 1999;20:229-236.
112. Yagmur Y, Prasad MJ, **Osborne MP**.
Myofibroblastoma in the irradiated breast.
Breast Journal 1999;5:136-140.
113. Taioli E, Bradlow HL, Garbers VV, Sepkovic DW, **Osborne MP**, Trachman J, Ganguly S, Garte SJ.
Role of estradiol metabolism and CYP1A1 polymorphisms in breast cancer risk.
Cancer Detection and Prevention 1999;23:232-237.
114. Giess CS, Keating DM, **Osborne MP**, Rosenblatt R.
Local tumor recurrence following breast-conservation therapy: Correlation of histopathologic findings with detection method and mammographic findings.
Radiology 1999;212:829-835.

115. Suto A, Telang NT, Tanino H, Takeshita T, Ohmiya H, **Osborne MP**, Kubota T.
In vitro and in vivo modulation of growth regulation in the human breast cancer cell line MCF-7 by estradiol metabolites.
Breast Cancer – Journal of the Japanese Breast Cancer Society 1999;6:87-92
116. Simmons RM, Fish SK, Gayle L, LaTrenta GS, Swistel A, Christos P, **Osborne MP**. Local and distant recurrence rates in skin-sparing mastectomies compared with non-skin-sparing mastectomies.
Annals of Surgical Oncology 1999;6:676-681
117. Simmons RM, **Osborne MP**.
The evaluation of high risk and pre-invasive breast lesions and the decision process for follow up and surgical intervention.
Surgical Oncology 1999;8:55-65
118. Prasad ML, **Osborne MP**, Giri DD, Hoda SA.
Microinvasive carcinoma (T1mic) of the breast: Clinicopathologic profile of 21 Cases.
American Journal of Surgical Pathology 2000;24:422-428.
119. Shin SJ, **Osborne MP**, Moore A, Hayes MK, Hoda SA.
Determination of size in invasive breast carcinoma: Pathologic considerations and clinical implications.
American Journal of Clinical Pathology 2000;113:S19-29
120. Saqi A, **Osborne MP**, Rosenblatt R, Shin SJ, Hoda SA.
Quantifying mammary duct carcinoma in situ: A wild goose chase?
American Journal of Clinical Pathology 2000;113:S30-37
121. Rivadeneira DE, Simmons RM, Christos PJ, Hanna K, Daly JM, **Osborne MP**.
Predictive factors associated with axillary lymph node metastases in T1a and T1b breast carcinomas: Analysis in more than 900 patients.
Journal of the American College of Surgeons 2000;191:1-8
122. Rivadeneira DE, Simmons RM, Fish SK, Gayle L, La Trenta GS, Swistel A, **Osborne MP**.
Skin-sparing mastectomy with immediate breast reconstruction: A critical analysis of local recurrence.
Cancer Journal 2000;6:331-35
123. Telang NT, Katdare M, Bradlow HL, **Osborne MP**.
Cell cycle regulation, apoptosis and estradiol biotransformation: novel endpoint biomarkers for human breast cancer prevention.
Journal of Clinical Ligand Assay 2000;23:130-137
124. Giess CS, Keating DM, **Osborne MP**, Mester J, Rosenblatt R.
Comparison of rate of development and rate of change for benign and malignant breast calcifications at the lumpectomy bed.
American Journal of Roentgenology 2000;175:789-93.
125. Rosenbaum Smith SM, **Osborne MP**.
Breast cancer chemoprevention.
American Journal of Surgery 2000;180:249-251

126. Simmons R, Hoda S, **Osborne MP**.
Bone marrow Micrometastases in breast cancer patients.
American Journal of Surgery 2000;180:309-312
127. Shaikh N, LaTrenta G, Swistel A, **Osborne MP**.
Detection of recurrent breast cancer after TRAM flap reconstruction.
Annals of Plastic Surgery 2001; 47:602-607
128. Simmons RM, Brennan MB, Christos P, Skolnick M, **Osborne MP**.
Recurrence rates in patients with central or retroareolar breast cancers treated with mastectomy or lumpectomy.
American Journal of Surgery 2001; 182:325-329
129. Simmons RM, Smith SM, **Osborne MP**.
Methylene blue dye as an alternative to isosulfan blue dye for sentinel lymph node localization.
Breast Journal 2001; 7:181-183
130. Simmons R, Brennan M, Christos P, King V, **Osborne MP**.
Analysis of nipple/areolar involvement with mastectomy: Can the areola be preserved?
Annals of Surgical Oncology 2002; 9:165-168
131. Jinno H, Steiner MG, Nason-Burchenal K, **Osborne MP**, Telang NT.
Preventive efficacy of receptor class selective retinoids on HER-2/neu oncogene expressing preneoplastic human mammary epithelial cells.
International Journal of Oncology 2002; 21:127-134
132. Katdare M, **Osborne MP**, Telang NT
Soy isoflavone genistein modulates cell cycle progression and induces apoptosis in HER-2/neu oncogene expressing human breast epithelial cells.
International Journal of Oncology 2002; 21:809-815
133. Narod SA, Dubé MP, Klijn J, Lubinski J, Lynch HT, Ghadirian P, Provencher D, Heimdal K, Moller P, Robson M, Offit K, Isaacs C, Weber B, Friedman E, Gershoni-Baruch R, Rennert G, Pasini B, Wagner T, Daly M, Garber JE, Neuhausen SL, Ainsworth P, Olsson H, Eavns G, **Osborne MP**, Couch F, Foulkes WD, Warner E, Kim-Sing C, Olopade O, Tung N, Saal HM, Weitzel J, Merajver S, Gauthier-Villars M, Jernstrom H, Sun P, Brunet JS
Oral Contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Journal of the National Cancer Institute 2002; 94:1773-1779
134. Simmons R, Adamovich T, Brennan M, Christos P, Schultz M, Eisen C, **Osborne MP**
Nonsurgical evaluation of pathologic nipple discharge.
Annals of Surgical Oncology 2003; 10:113-116
135. Simmons R, Thevarajah S, Brennan MB, Christos P, **Osborne MP**
Methylene blue dye as an alternative to isosulfan blue dye for sentinel lymph node localization.
Annals of Surgical Oncology 2003; 10:208-9
136. Hollenbeck ST, Cellini C, Christos P, Varnado-Rhodes Y, Martins D, Nussbaum M, **Osborne MP**, Simmons R.
Breast cancer in patients with residual invasive carcinoma is more accurately staged with additive tumor size Assessment.
Annals of Surgical Oncology 2003; 11:59-64

137. Sauven P, on behalf of the Association of Breast Surgery Family History Guidelines Panel (Osborne MP et al)
Guidelines for the management of women at increased familial risk of breast cancer
European Journal of Cancer 2004; 40:653-665

Non Peer Reviewed Publications

1. **Osborne MP**
Drug Addiction.
Charing Cross Hospital Gazette 1969;128-130
2. **Osborne MP**
Three unusual cases presenting with abdominal swelling.
Charing Cross Hospital Gazette Clinical and Scientific Supplement No. II. 1970;5-14
3. **Osborne MP**, Sanderson FM.
High serum acid phosphatase levels (letter).
Lancet 1973;ii:802
4. **Osborne MP**.
Diseases of the breast.
Monthly Index of Medical Specialties 1978;275-285
5. **Osborne MP**.
The scope of surgical oncology (editorial).
Clinical Oncology 1979;3:199-200
6. **Osborne MP**, Ryman BE, Payne JH, McCready VR.
The use of ^{99m}Tc-labelled neutral liposomes in lymphoscintigraphy: a comparison of scintigram interpretations with node histology in a series of breast cancer patients.
In: Progress in Radiopharmacology. Ed: PM Cox. Elsevier / North Holland Biomedical Press 1981;2:317-325
7. **Osborne MP**, Meijer WS, Yeh DJ, DeCosse JJ.
Lymphoscintigraphy in the staging of solid tumors.
Surgery, Gynecology and Obstetrics 1983;158:384-391
8. **Osborne MP**.
Controversies in the management of primary breast cancer.
Cancer Investigation 1983;1:259-265
9. Recabaren J, **Osborne MP**, DeCosse JJ.
Individuals at High Risk - Preventive Measures.
In: Series: New Horizons in Oncology. Ed: B Stoll. Vol 3: Risk Factors in Multiple Cancer. Wiley, London, 198, pp 263-275.
10. **Osborne MP**.
Limited resection and radical radiation therapy in the treatment of early stage breast cancer.
Problems in General Surgery 1985;2:159-166
11. **Osborne MP**, Crowe JP.
The identification of enhanced risk patients and their management in a special surveillance breast clinic.
In: Breast Cancer: Diagnosis and Treatment. Eds: IM Ariel, JB Cleary. McGraw Hill, New York, 1987, pp75-86.

12. **Osborne MP.**
The biological basis for breast cancer treatment options.
American College of Surgeons Bulletin 1986;7:4-14
13. **Osborne MP, Andrakis C, Nonkin R.**
The thermal scalpel: A comparative study with the conventional scalpel and the electrocautery.
Contemporary Surgery 1986;29:51-54
14. **Osborne MP.**
Breast development and anatomy.
In: Breast Diseases. Eds: J Harris, S Hellman, C. Henderson, D Kinne. Lippincott, Philadelphia 1987, pp 1-14.
15. Williams WR, **Osborne MP.**
Familial aspects of breast cancer: An overview.
In: Breast Diseases. Eds: J Harris, S Hellman, C Henderson, D Kinne. Lippincott, Philadelphia 1987, pp 109-120.
16. **Osborne MP.**
Prophylactic mastectomy.
In: Breast Diseases. Eds: J Harris, S Hellman, C Henderson, D Kinne. Lippincott, Philadelphia 1987, pp 120-121.
17. **Osborne MP, Bayle J-C.**
Prophylactic mastectomy: Rarely indicated in the non-affected patient.
Primary Care and Cancer 1988;8:25-31
18. **Osborne MP, Axelrod DM.**
Control of local infection and necrosis.
In: Manual of Oncologic Therapeutics. Ed: RE Wittes. Lippincott, Philadelphia 1989-1990, pp 550-56.
19. **Osborne MP, Axelrod DM.**
The swollen extremity.
In: Manual of Oncologic Therapeutics. Ed: RE Wittes. Lippincott, Philadelphia 1989-1990, pp 565-68.
20. **Osborne MP.**
Sarcoma of the breast.
In: Surgical Management of Soft Tissue Sarcoma. Eds: MH Shiu, MF Brennan. Lea and Febiger, Philadelphia 1989, pp 216-234.
21. Telang NT, Bockman RS, Modak MJ, **Osborne MP.**
The role of fatty acids in murine and human mammary carcinogenesis: An in vitro approach.
In: Carcinogenesis and Dietary Fat. Eds: S Abraham, L Marnett, K Hohn. Kluwer Academic Publishers, Boston 1989, pp 427-451.
22. Dershaw DD, **Osborne MP.**
Clinical aspects of imaging techniques in breast cancer.
Seminars in Surgical Oncology 1989;5:82-93

23. **Osborne MP**, Hundahl SA, Urban JA.
Radical surgery: Rationale, indications and techniques.
In: Current Treatment of Cancer: Breast Cancer. Eds. B Hoogstraten, JI Burn, HJG Bloom. UICC, Springer-Verlag, Berlin 1989, pp 133-160
24. **Osborne MP**, Borgen PI.
The role of mastectomy in the treatment of breast cancer.
Surgical Clinics of North America 1990;70:1023-1046
25. **Osborne MP**.
Small-size breast cancer (3 cm. mass). When is conservative therapy not appropriate
In: Common Problems in Cancer Surgery. Ed: H Wanebo. Year Book Medical Publishers, Chicago 1990, pp 24-29
26. **Osborne MP**.
Intermediate-size breast cancer. When is breast conservation not indicated?
In: Common Problems in Cancer Surgery. Ed: H Wanebo. Year Book Medical Publishers, Chicago 1990, pp 30-34
27. **Osborne MP**, Telang NT.
Primary prevention of breast cancer.
In: The Breast: Comprehensive Management of Benign and Malignant Diseases. Eds: KI Bland, EM Copeland. WB Saunders, Philadelphia 1991, pp 246-261
28. Telang NT, Basu A, Modak MJ, Bradlow HL, **Osborne MP**.
Fatty acid-induced modulation of carcinogenesis in human and murine mammary explant cultures.
In: Eicosanoids and Other Bioactive Lipids in Cancer and Radiation Injury. Eds: KV Honn, LJ Marnett, S Nigam, T Walden. Kluwer Academic Publishers, Boston 1991;15:93-102
29. Axelrod DM, **Osborne MP**.
Control of infection and necrosis.
In: Manual of Oncologic Therapeutics. Ed: RE Wittes. Lippincott, Philadelphia 1991-1992, pp 395-402
30. Axelrod DM, **Osborne MP**.
The swollen extremity.
In: Manual of Oncologic Therapeutics. Ed: RE Wittes. Lippincott, Philadelphia 1991-1992, pp 405-407
31. Cote RJ, Rosen PP, Old LF, **Osborne MP**.
Detection of bone marrow micrometastases in patients with early-stage breast cancer.
Diagnostic Oncology 1991;1:37-42
32. **Osborne MP**.
Salvage mastectomy.
Seminars in Surgical Oncology 1991;7:291-295
33. **Osborne MP**.
Breast development and anatomy.
In: Breast Diseases, 2nd Edition. Eds: J Harris, S Hellman, C Henderson, D Kinne. Lippincott, Philadelphia 1991, pp 1-13

34. Bradlow HL, **Osborne MP**, Michnovicz JJ, Telang NT.
Modulation of estrogen metabolism: Possible application to the chemo-prevention of breast cancer.
In: Hormonal Carcinogenesis. Eds: JJ Li, S Nardi, SA Li. Springer-Verlag, New York 1992, pp 89-111
35. Telang NT, **Osborne MP**.
Ras oncogene: A novel molecular biomarker for breast cancer susceptibility and prevention.
In: Current Perspectives on Molecular and Cellular Oncology. Ed: DA Spandidos. JAI Press Ltd., London 1992, pp 95-117
36. Telang NT, Basu A, Wong GY, Bradlow HL, **Osborne MP**.
Chemopreventive modulation of human mammary carcinogenesis by bioactive lipids.
In: Proceedings of II International Conference on Eicosanoids and other Bioactive Lipids in Cancer. Eds: S Nigam, KV Hunn, LJ Marrell, TL Walden. Kluwer Academic Publishers, Boston 1992, pp 439-446
37. **Osborne MP**, Borgen PI.
Atypical ductal and lobular hyperplasia and breast cancer risk.
Surgical Oncology Clinics of North America 1993;2: 1-11
38. Brady MS, **Osborne MP**.
The biological basis of breast cancer treatment.
Surgical Rounds 1993;16:27-33
39. **Osborne MP**, Hoda S.
Current management of lobular carcinoma in situ of the breast.
Oncology 1994;8:45-49
40. Whalen GF, **Osborne MP**.
Breast cancer: The oncologic surgeon's perspective.
In: Aesthetic Plastic Surgery, 2nd Edition. Eds: TD Rees, GS LaTrenta. WB Saunders, Philadelphia 1994, pp 1050-1061
41. Axelrod DM, **Osborne MP**
The swollen extremity.
In: Manual of Oncologic Therapeutics. JB Lippincott, Philadelphia 1995, pp 452-455
42. **Osborne MP**
Breast Development and Anatomy.
In: Diseases of the Breast, Eds: J Harris, M Lippman, M Morrow, S Hellman. Lippincott, Philadelphia 1996, pp 1-14
43. Oliveria SA, **Osborne MP**.
Diet, breast cancer and case-control studies
Lancet 1996;347:1346
44. Davis DL, Axelrod D, **Osborne MP**, Telang NT.
Environmental influences on breast cancer risk
Science & Medicine May/June 1997; 56-63

45. **Osborne MP.**
Ethical dilemmas of BRCA testing in breast cancer.
Cancer Case Presentations: The Tumor Board 1997;1:11
46. **Osborne MP, Boyle P, Lipkin M.**
Cancer prevention.
Lancet 1997; 349 (suppl. II):27-30
47. **Osborne MP.**
Breast cancer gene testing: Pain or gain? (editorial)
Contemporary Surgery 1997;60:312
48. Bradlow HL, Davis D, Sepkovic DW, Tiwari R, **Osborne MP.**
Role of the estrogen receptor in the action of organochlorine pesticides on estrogen metabolism in human breast cancer cell lines.
The Science of the Total Environment 1997;208: 9-14
49. Simmons RM, **Osborne MP.**
Treatment of recurrent ductal carcinoma in situ.
In: Ductal Carcinoma In Situ of the Breast. Ed: MJ Silverstein. Williams & Wilkins, Baltimore, Maryland 1997, pp 569-575
50. Katdare M, **Osborne MP, Telang NT.**
Inhibition of aberrant proliferation and induction of apoptosis in pre-neoplastic human mammary epithelial cells by natural phytochemicals
Oncology Reports 1998;5:311-315
51. Simmons RM, **Osborne MP.**
Surgical treatment of minimal breast cancer.
In: Early breast cancer. Eds: MWE Morgan, R Warren, G Querci della Rovere. Harwood Academic Publishers, Singapore 1998, pp 205-213
52. Prasad ML, **Osborne MP, Hoda SA.**
Observations on the histopathologic diagnosis of microinvasive carcinoma of the breast.
In: Anatomic Pathology 1998, Vol. Three. Eds: RE Fechner, PP Rosen. ASCP Press, Chicago, 1998, pp 209-232
53. Reichman BS, **Osborne MP.**
Detection of occult micrometastatic disease.
In: The Breast. Comprehensive management of benign and malignant diseases. Eds: KI Bland, EM Copeland. WB Saunders, Philadelphia 1998, pp 1299-1303
54. Benson JR, **Osborne MP.**
Breast cancer therapy.
Lancet (Letter) 1998;351:145
55. Robertson J, Howell A, **Osborne MP.**
Is tamoxifen of value in patients who have received breast conservation for localised DCIS?
Breast Cancer On-Line www.bco.org 1999.

56. **Osborne MP.**
Chemoprevention of breast cancer.
Surgical Clinics of North America 1999; 79:1207-1221
57. Benson JR, **Osborne MP.**
Angiosarcoma in BRCA1 and 2 carriers.
Breast Cancer Research and Treatment (Letter) 1999;55:293.
58. **Osborne MP.**
Breast cancer prevention by antiestrogens.
Annals of the New York Academy of Sciences 1999;889:146-151
59. **Osborne MP.**
Breast Development and Anatomy.
In: Diseases of the Breast, 2nd Edition. Eds: J Harris, M Lippman, M Morrow, S Hellman, MP Osborne.
Lippincott, Philadelphia 1999, pp 1-31.
60. Katdare M, Jinno H, **Osborne MP**, Telang NT.
Negative growth regulation of oncogene-transformed human breast epithelial cells by phytochemicals: role of apoptosis.
Annals of the New York Academy of Science 1999;889:247-252
61. Bradlow HL, Sepkovic DW, Telang NT, **Osborne MP.**
Multifunctional aspects of the action of Indole-3-Carbinol as an antitumor agent.
Annals of the New York Academy of Sciences 1999;889:204-213
62. Bradlow HL, Telang NT, Sepkovic DW, **Osborne MP.**
Phytochemicals as modulators of cancer risk. Advances in Nutrition and Cancer 2. Ed: Zappia et al.
Kluwer Academic / Plenum Publishers, New York, 1999.
63. **Osborne M.**
Micrometastatic cancer in bone marrow: A predictor of prognosis.
XI International Congress of Senology. Eds Basurto CS, Cwilich RG, Forgach ES.
Cancun, Mexico, May 13-18, 2000, p43.
64. Singhal H, **Osborne M.** Bone Marrow Micrometastases Detection and Significance. In: Cancer Metastasis, Molecular and Cellular Mechanisms and Clinical Intervention. Eds. WG Jiang, RE Mansel. Kluwer Academic Publishers, Dordrecht, The Netherlands, 2000, pp 215-224.
65. Kash KM, Ortega-Verdejo K, Dabney MK, Holland JC, Miller DG, **Osborne MP.**
Psychosocial aspects of cancer genetics: Women at high risk for breast and ovarian cancer.
Seminars in Surgical Oncology 2000;18:333-338.
66. Rosenbaum Smith SM, **Osborne MP**,
Screening for breast cancer.
In: Current Surgical Therapy 7th Edition. Ed: Cameron JL, Mosby, St. Louis 2001, pp 693-696

67. Simmons R, **Osborne MP**.
Bone marrow aspiration as an adjunct to staging by sentinel lymph node biopsy in breast cancer patients.
Seminars in Breast Disease 2002; 5:47-52
68. Simmons R and **Osborne M**
Diseases of the breast
In Conn's Current Therapy Eds: Rakel RE and Bope ET: 2003; 1125-1130
69. **Osborne MP**. Editor
Breast cancer prevention
Seminars in Breast Disease 2003 volume 6
70. **Osborne MP**
Prohylactic mastectomy
In Seminars in Breast Disease 2003; 6:34-40
71. Simmons R and **Osborne M**
Diseases of the Breast
In Conn's Current Therapy Eds: Rakel RE and Bope ET: 2004 ; 1093-1099

Presentations

- 4/3/91 National Consortium of Breast Centers – Knoxville, TN
Keynote Speaker
The identification, management and strategies for prevention of women at increased risk for breast cancer: the role of the breast center.
- 3/12/92 New York Hospital – Cornell Medical Center – New York, NY
Public Service Seminar
What every woman should know about breast cancer.
- 4/29/92 National Council of Women of the United States, Inc. – New York, NY
Prevention and early detection of breast cancer.
- 5/14-15/92 European School of Oncology – Memorial Sloan-Kettering Cancer Center – New York, NY
Postgraduate Course: Conservative Treatment in Breast Cancer
Management of local recurrence.
- 6/24-26/92 Cancer Micrometastases: Biology, Methodology, and Clinical Significance – NCI, Bethesda, MD
Early clinical experience with breast cancer.
General methodological aspects: sensitivity.
- 9/09/92 Northshore University Hospital – Manhasset, NY
Grand Rounds Lecture
Breast cancer micrometastases in bone marrow: a predictor of early relapse.
- 10/8-9/92 Inštitút pre ďalšie vzdelávanie pracovníkov v zdravotníctve v Bratislave
Bratislava, Slovakia
Overview of risk factors for breast cancer and screening.
Current techniques of breast conservation, management of local recurrence and prevention of metastasis.
- 11/30/92 New York Roentgen Society – New York, NY
Surgical management of carcinoma in-situ.
- 12/8-10/92 15th Annual San Antonio Breast Cancer Symposium – San Antonio, TX
Immunofluorescent monoclonal antibody detection of breast cancer, bone marrow micrometastases in patients with unilateral invasive breast cancer: distribution by TNM Stage.
- 2/7-15/93 Kurume University and Keio University Hospital, Japan - Zen-Yaku Pharmaceutical Co. Ltd.,
The estrogen metabolite 16-alpha- hydroxyestrone: an initiator/promoter of breast cancer?
Bone marrow micrometastasis detected by monoclonal antibodies predict the early relapse of breast cancer.
- 2/15–18/93 Kwong Wah Hospital – Hong Kong
New approaches to breast cancer induction and detection of occult metastasis.

- 2/27/93 The 20th Annual Breast Cancer Symposium - New York Metropolitan Breast Cancer Group, New York, NY
The NSABP Trials.
- 4/30/93 American College of Surgeons – Hershey, PA
A comparison of the results with different modalities of treatment in Stage I & II breast cancer.
Management of nipple discharge.
Management of recurrent local disease after breast preserving procedures.
- 5/6/93 New York Roentgen Society – New York, NY
Surgical management of advanced breast cancer.
- 5/6-7/93 European School of Oncology – Memorial Sloan-Kettering Cancer Center, New York, NY
Postgraduate course: Controversies in Breast Cancer
The biological basis of local-regional treatment options.
- 9/29/93 American Cancer Society – Rockefeller University, New York, NY - Cancer Prevention and Early Detection: Practice Perspectives, Controversies and Future Directions
Controversies in breast cancer prevention.
- 10/2-5/93 New York Clinical Society New York, NY
Breast cancer: the history of surgical oncology.
- 10/4-8/93 European School of Oncology – Orta San Giulio, Italy
Breast Cancer Co Chairperson.
The importance of local regional treatment in the natural history of breast cancer.
Round table: Premalignant lesions, in-situ breast carcinoma: biological behavior and management.
Risk factors and management of breast recurrences after conservative treatment.
- 10/10-15/93 American College of Surgeons Annual Meeting – San Francisco, CA
Proliferative breast disease and cancer risk.
- 10/31-11/8/93 Postgraduate Course: Argentine Society of Mastology Buenos Aires, Argentina
Keynote Lecture
Chemoprevention in breast cancer.
Identification and management of women at risk for breast cancer.
Epidemiology in breast pathology.
An overview of the biological basis of breast cancer treatment.
Current indications of mastectomy.
- 11/18-19/93 British Association of Cancer Research/British Association of Surgical Oncology Science Forum – London, UK
Modulators of mammary epithelial growth and transformation.
- 11/30/93 3rd Annual Solid Tumor Symposium – New York Medical College/Westchester County Medical Center, Valhalla, NY
Bone marrow micrometastases: a predictor of breast cancer recurrence?

- 3/9/94 New York Hospital/Cornell Medical Center – Division of Plastic Surgery, New York, NY
Mastectomy and breast surgery.
- 3/9/94 New York Surgical Society – New York, NY
Discussant
Ultrasound-guided fine needle aspiration cytology – early experience with a new and logical approach.
- 4/5/94 Grand Rounds, Hackensack Medical Center – Hackensack, NJ
Bone marrow micrometastases in breast cancer as a predictor of early relapse.
- 4/11/94 MedCom Systems, Inc. National Teleconference “Advances in Screening, Diagnosis, and Treatment of Breast Cancer” Philadelphia, PA
Breast cancer surgical treatment.
- 5/8-12/94 8th International Congress on Senology (Breast Diseases) of The Senologic International Society (SIS) – Rio de Janeiro, Brazil
Primary Prevention in Breast Cancer: Diet and nutritional factors.
Breast Cancer Therapy: Discussant.
Epidemiology of Breast Cancer: Identification and management of women at increased risk.
Local Recurrences: Contralateral breast approach.
Controversies in Breast Cancer Treatment: Biological basis for breast cancer treatment options.
- 10/1/94 Frontiers in oncology-hematology New York Hospital/Cornell Medical Center – New York, NY
Breast cancer.
- 10/3-5/94 European School of Oncology, Milan, Italy - Advanced Course: Breast Cancer - Co-Chairperson.
The importance of local regional treatment on the natural history of breast cancer.
Risk factors and management of breast recurrences.
- 10/12/94 80th Annual Clinical Congress American College of Surgeons, Chicago, IL
Postgraduate Course: Breast Surgery
Breast conservation: predictors and management of local recurrence.
- 10/25/94 Grand Rounds – Lenox Hill Hospital, New York, NY
Breast cancer risk: management and psychological issues.
- 11/16/94 Department of Surgery Grand Rounds – Brown University Medical College/Rhode Island Hospital, Providence, RI
Bone marrow micrometastases: a predictor of systemic disease.
- 12/15/94 3rd Annual Cyril S. Arvanitis Lectureship Program - Monmouth Surgical Society, Long Branch, NJ
Breast cancer: past, present and future.

- 1/29-2/3/95 20th Annual Post-Graduate Course: – New York Hospital/Cornell University Medical College, Aruba - Diagnostic Imaging – Current Status in Selected Topics with Treatment Commentaries
Breast conserving surgery and radiation therapy.
Identification and management of women at enhanced risk for breast cancer.
Biological basis of breast cancer treatment options.
- 2/24-25/95 17th Annual Oncology Update: New Diagnostic Treatments and Techniques for Cancer and Treatment of Early Diagnosed Cancer – Miami, FL
The identification and management of patient at increased risk for breast cancer.
Detection of bone marrow micrometastases: a new prognostic variable.
- 3/10-11/95 American Society of Breast Disease Annual Meeting, New York Metropolitan Breast Cancer Group & Memorial Sloan-Kettering Cancer Center – New York NY
Dilemmas in surgery and radiation therapy.
- 4/1-6/95 E. Majorana Centre for Scientific Culture, International School of Pharmacology, Erice, Sicily Propedeutics to Cancer Management – Co-Chairman of Session
Hormonal interventions in breast cancer: past, present and future.
- 5/20-23/95 American Society of Clinical Oncology – Los Angeles, CA
Abstract Discussion Leader.
High dose therapy.
- 6/1/95 Surgical Oncology Grand Rounds - Maimonides Medical Center, Brooklyn, NY
Bone marrow micrometastases.
- 9/26/95 Northshore University Hospital, Oncology Conference – Manhasset, NY
Identification and management of women at risk for breast cancer in the era of molecular genetics.
- 11/8/95 Division of Plastic Surgery Grand Rounds New York Hospital/Cornell Medical Center, New York, NY
Breast cancer.
- 2/23/96 Division of Neoplastic Diseases Grand Rounds - Mount Sinai Medical Center, New York, NY
Prognostic and therapeutic implication of occult bone marrow micrometastases.
- 4/16/96 Postgraduate Courses: Update on the Treatment of Cancer of the Colon and Breast - American College of Surgeons – New York, NY
Identification and management of women at risk for breast cancer in the era of molecular genetics.
- 6/28-29/96 Hokkaido University – Sapporo, Japan
Identification and management of women at risk for breast cancer in the era of molecular genetics.

- 10/6-11/96 Breast Disease - American College of Surgeons – San Francisco, CA
Postgraduate Course: Management of the abnormal screening mammogram.
- 10/31/96 Chemotherapy Foundation Symposium – Innovative Cancer Therapy for tomorrow – The Division of Neoplastic Diseases/Mount Sinai School of Medicine, New York, NY
Prognostic and therapeutic implications of bone marrow micrometastases.
- 12/13/96 1st Network New York Hospital/Cornell Medical Center Seminar: Advances in Oncology – New York, NY
Breast cancer treatment outcome analysis.
- 2/12/97 United Hospital - Mamaroneck, NY
Recent progress in breast cancer risk evaluation, prevention, early diagnosis and treatment.
- 1/26-31/97 25th Anniversary Diagnostic Radiology Postgraduate Course: The New Wave in Diagnosis and Treatment – Department of Radiology, Cornell University Medical College & the New York Hospital, Puerto Rico
Special Lecture: Halsted: personal tragedy to professional triumph
Breast cancer biology: indications for treatment
Identification and management of women at risk for breast cancer in the molecular era
Precursor lesions for breast carcinoma: diagnosis and treatment.
- 2/25/97 Surgical Grand Rounds - New York Methodist Hospital, Brooklyn, NY
Bone marrow in breast cancer prognostic and therapeutic implications.
- 3/6-8/97 14th Annual Miami Breast Cancer Conference – Miami, FL
Halsted: Personal tragedy to professional triumph.
- 10/31-11/4/97 US Army Medical Research and Material Command's 1997 Meeting: DOD Breast Cancer Research Program: An Era of Hope" Department of Defense, Washington, DC
Identification of primary tumor markers in occult bone marrow micrometastases.
- 12/12/97 2nd Annual Seminar on Advances in Oncology Breast Cancer Management Today and Tomorrow – New York Hospital/Cornell Medical Center, New York, NY
New perspectives in the management of breast cancer.
- 6/19/98 Surgery Update 1998 – New York Hospital/Cornell Medical Center, New York, NY
Halsted in NY... an historic view.
- 6/10-12/98 Schweitzer Seminar on Cancer – Prague, Czech Republic
Epidemiology, prevention and early detection of breast cancer.
- 9/10/98 Emerging Strategies for Cancer Therapy in the New Millenium – New York Methodist Hospital, Brooklyn, NY
Selective axillary lymph node dissection: the role of sentinel node biopsy.
- 10/7/98 The Latest News About Breast Cancer Prevention, Diagnosis And Treatment – New York Hospital/Cornell Medical Center & Strang Cancer Prevention Center, New York, NY

Prevention strategies.

- 10/25-30/98 American College of Surgeons Annual Meeting, Orlando, FL
Breast Disease Postgraduate Course:
Who doesn't need adjuvant chemotherapy: the role of novel prognostic markers?
- 11/21-22/98 1st Roche International Symposium on Cancer Research – Kyoto, Japan
Chemoprevention of breast cancer.
- 12/9-11/98 15th Annual Controversies, Problems and Techniques in Surgery – Albert Einstein College of Medicine, Montefiore Medical Center, New York, NY
Controversy: Axillary Dissection in early Stage Breast Cancer: To Do or Not To Do?: Selective Management of the Regional Nodes
Problems in Breast Surgery: Identification of Increased Risk of Breast Cancer and Strategies for Prevention. Panel Discussant.
- 5/12/99 Public Education Meeting – SHARE Program/Lord & Taylor, New York, NY
New frontiers: nutritional and pharmacological means to reduce risk of breast cancer.
- 6/16-18/99 63rd Annual Course in Advances in Breast, Endocrine and Cancer Surgery University of Minnesota, Minneapolis, MN
Risk factors in breast cancer and the role of genetics.
Are biological markers of significant practical value in breast cancer?
Panelist.
- 3/2-4/00 17th Annual Miami Breast Cancer Conference – Miami, FL
Moderator of special session on sentinel nodes
Overview of breast cancer prevention.
Value of prognostic markers including the role of bone marrow micrometastases.
Pitfalls in the management of breast cancer: a medical/legal perspective.
Umberto Veronesi: a man for all seasons.
- 4/14-15/00 Annual Meeting American Society of Breast Surgeons – Charleston, SC
Chemoprevention in the management of high-risk patients
Medical-legal aspects of breast cancer treatment.
Micrometastatic cancer in bone marrow – a predictor of prognosis.
- 5/2/00 Surgical Grand Rounds Hackensack Medical Center, Hackensack, NJ
Preventing breast cancer.
- 5/14-18/00 IX International Congress of Senology, – Cancun, Mexico
Keynote Lecture – Women at High Risk for Breast Cancer: Identification and Management
Axillary dissection
Cancer prevention.
Bone marrow micrometastases: a prognostic factor for breast cancer?
- 6/10/00 Breast Imaging Seminar New York Roentgen Society, New York, NY
Breast cancer treatment today: surgery, radiation and chemotherapy.
- 6/14-16/00 2nd Milan Breast Cancer Conference - Milan, Italy The role of the internet.
Satellite Symposium on Breast Cancer and the Media: a Challenge for Doctors and Nurses

- 10/19/00 Irish Traveling Surgeons – NewYork-Presbyterian Hospital/NY Weill Cornell Center/Weill Medical College of Cornell University, New York, NY
Chemoprevention of breast cancer.
- 10/21/00 Cornell Medical Center Alumni Symposium: Women’s Health in the New Millennium –Weill Medical College of Cornell University, New York, NY
Substitute speaker for Antonio Novella, MD. New York State Health Commissioner
Opening remarks.
- 10/23/00 42nd Annual Meeting of the American Society for Therapeutic Radiology and Oncology Boston, MA
Breast cancer case management panel in early stage invasive breast cancer (AJCC Stages III) and duct carcinoma in-situ (Stage 0).
- 2/15/01 Cancer & Fertility: The Latest Options – Resolve NYC, New York, NY
Panelist.
- 3/16/01 Royal College of Surgeons of England – NewYork Weill Cornell Center, New York, NY
The Surgeon in the Breast Cancer Patient’s Journey.
- 3/21/01 Department of Radiation Oncology Grand Rounds New York Methodist Hospital, Brooklyn, NY
Identification and management of women at increased risk of breast cancer.
- 3/24-28/01 American Association for Cancer Research, New Orleans, LA - Progress and New Hope in the Fight Against Cancer: A Public Forum Highlighting the Latest Discoveries: Ask the Experts –
Breast cancer: early detection of metastases.
- 4/27/01 Cancer Genetics & Genomics – Weill Medical College, New York, NY
Hereditary breast cancer.
The individual at risk: a case study.
Gene testing and the surrounding issues.
Using the knowledge: follow-up and patient care.
- 4/27-29/01 25th Annual Meeting of the American Society of Breast Disease
New York, NY
Micrometastases’ prognostic and therapeutic implications.
Moderator.
- 4/30/01 New York Clinical Society New York, NY
The Hunters: brother surgeons.
- 5/17/01 Surgical Grand Rounds – New York Hospital/Cornell Medical Center, New York, NY
Bone marrow micrometastases.
- 6/13-15/01 3rd Milan Breast Cancer Conference – Milan, Italy
Bone marrow micrometastases.
- 10/14/01 7th Annual Breast Cancer Awareness Day SASS Foundation, Huntington, NY
Eileen Dryer Memorial Lecture – Keynote Speaker.
Advancements in the management of breast cancer.

- 12/5-7/01 18th Annual Controversies, Problems and Techniques in Surgery – Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY
Bone marrow micrometastases: diagnosis at surgery.
Role of tamoxifen as adjuvant therapy and chemoprevention.
Panelist.
- 2/14-16/02 Tumor Prevention and Genetics 2002: International Society for Cancer Chemoprevention, St Gallen, Switzerland
Secondary prevention of breast cancer: the mammography controversy.
Moderator.
- 3/3-5/02 Lung Screening Seminar, Paris, France
Speaker and Workshop Chair.
Principal measure of breast cancer screening's usefulness.
- 4/26/02 Cancer Genetics and Cancer Genomics Weill Medical College, New York, NY
Hereditary breast cancer.
Case study: the individual at risk and family issues.
Gene testing and the surrounding issues.
Sporadic breast cancer.
Management of node negative breast cancer.
- 4/28/02 3rd Annual Scientific Meeting - American Society of Breast Surgeons, Boston, MA
Clinical significance of circulating tumor cells
Bone marrow micrometastases.
- 5/18-21/02 American Society of Clinical Oncology – Orlando, FL
Poster Session.
Breast cancer bone marrow micrometastases: a long-term prognostic study of systemic tumor cell burden in relapse.
- 5/30/02 Department of Surgery Grand Rounds – New York Hospital/Cornell Medical Center, New York, NY
Anatomy of a surgical malpractice trial.
- 10/6-10/02 Postgraduate Course #30 – A Surgeon's Personal Guide to Risk management and Trial Participation - American College of Surgeons Clinical Congress – San Francisco, CA
Mock Trial: Summary of the Facts. Defendant.
- 10/14-18/02 Frontiers in Cancer Prevention Research: Genetics, Risk Modeling, Molecular Targets for Chemoprevention, Behavioral Prevention Research, Clinical Prevention Trials, Science and Public Policy – American Association for Cancer Research Boston, MA
Chairperson
Symposium: The Role of Prophylactic Surgery in Cancer Prevention.
- 10/17/02 The National Council on Women's Health Making Decisions About Hormone Level Replacement Therapy? Ask the Experts – UN Plaza, New York, NY
Panelist.

- 11/11/02 Breast Cancer Orientation Course in Cooperation with the Brazilian Society of Mastology – Memorial Sloan-Kettering Cancer Center, New York, NY
Prognostic significance of bone marrow micrometastases.
Discussion and case presentation on a case of sentinel lymph node metastases.
- 3/5 – 3/9/03 The Society of Surgical Oncology Cancer Symposium – Meet the Professor
Los Angeles, CA
Early Stage Breast Cancer: Are Nodal and Bone Marrow Micrometastases Important?
- 3/25/03 New York Medical College, Dept of Surgery, Valhalla, NY
Grand Rounds
New Developments in Breast Cancer Research and Management.
- 4/29/03 New York Methodist Hospital, Brooklyn, NY
Grand Rounds
Breast Cancer: Current Update and Future Trends
- 6/11-6/13/03 67th Annual Course in Advances in Breast, Endocrine and Cancer Surgery, University of Minnesota Minneapolis, MN
Care of Women with BRCA I or BRCA II Mutations
Antiestrogen Trials in Prevention of Breast Cancer
Lecture
- 10/23/03 Breast Cancer and the Environment at the Carriage House
New York, NY
The Prevention of Breast Cancer: History, Screening and Nutrition
- 12/3-12/6/03 San Antonio Breast Cancer Symposium, San Antonio, TX
Bone marrow micrometastasis is a significant predictor of long-term relapse-free survival for breast cancer by a non-proportional hazards model.
- 3/16-3/20/04 4th European Breast Cancer Conference, Hamburg, Germany
Micrometastases in Bone Marrow
- 5/12-5/16/04 Catholic University of Rome Department of Surgical Sciences in cooperation with Komen Foundation, Rome, Italy